| scholarly article | Q13442814 |
| P2093 | author name string | Beverly E Barton | |
| Adetola L Shodeinde | |||
| P2860 | cites work | Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway | Q24305237 |
| CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer | Q24318511 | ||
| Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA | Q24336371 | ||
| Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3 | Q24600230 | ||
| JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis | Q24609999 | ||
| IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells | Q24794588 | ||
| Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines | Q24799458 | ||
| Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells | Q24802990 | ||
| Activation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation | Q27485121 | ||
| Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. | Q27851427 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. | Q53544139 | ||
| Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. | Q53654970 | ||
| JAK2 Mutations are present in all cases of polycythemia vera | Q58455709 | ||
| Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells | Q73574304 | ||
| Programmed Cell Death (Apoptosis) and Cancer Chemotherapy | Q73676812 | ||
| STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo | Q74649686 | ||
| Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors | Q78192920 | ||
| Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins | Q27860890 | ||
| A road map for those who don't know JAK-STAT | Q28201970 | ||
| CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients | Q28238474 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms | Q28271752 | ||
| Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 | Q28637521 | ||
| STATs and gene regulation | Q29547796 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| The STATs of cancer--new molecular targets come of age | Q29614601 | ||
| STATs in oncogenesis | Q29617571 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways | Q30470153 | ||
| Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis | Q33387514 | ||
| Negative regulation of the JAK/STAT pathway | Q33539658 | ||
| The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors | Q33613105 | ||
| Creation of a novel peptide with enhanced nuclear localization in prostate and pancreatic cancer cell lines | Q33732116 | ||
| Negative regulation of cytokine signaling: STAT-induced STAT inhibitor | Q33740225 | ||
| STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription | Q33767810 | ||
| Stat3 activation is required for cellular transformation by v-src | Q33786469 | ||
| The role of STATs in transcriptional control and their impact on cellular function | Q33941346 | ||
| JAK-STAT signaling activated by Abl oncogenes | Q33941370 | ||
| Modulation of STAT signaling by STAT-interacting proteins | Q33941428 | ||
| CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms | Q33944270 | ||
| Identification of an acquired JAK2 mutation in polycythemia vera | Q33947635 | ||
| Specific protection against breast cancers by cyclin D1 ablation | Q34082446 | ||
| Role of Src expression and activation in human cancer | Q34103650 | ||
| SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. | Q34194226 | ||
| STAT proteins: novel molecular targets for cancer drug discovery | Q34293579 | ||
| Regulation of the Jak2 tyrosine kinase by its pseudokinase domain | Q34508384 | ||
| Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention | Q34595904 | ||
| TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations | Q34633315 | ||
| Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells | Q34698039 | ||
| Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth | Q34922227 | ||
| Transcription factors as targets for cancer therapy | Q34932264 | ||
| StAT signaling in cancer: insights into pathogenesis and treatment strategies. | Q35076049 | ||
| Lack of toxicity of a STAT3 decoy oligonucleotide. | Q36175325 | ||
| Leukemia inhibitory factor-dependent transcriptional activation in embryonic stem cells | Q36254804 | ||
| Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders | Q36374813 | ||
| STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends | Q36922793 | ||
| JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials | Q36946580 | ||
| Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro | Q37385294 | ||
| Cell penetrating peptides: overview and applications to the delivery of oligonucleotides | Q37629659 | ||
| Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond | Q37833893 | ||
| Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis | Q38290076 | ||
| Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells | Q38302598 | ||
| Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. | Q38304535 | ||
| Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer | Q38315429 | ||
| Acute-Phase Response Factor, a Nuclear Factor Binding to Acute-Phase Response Elements, is Rapidly Activated by Interleukin-6 at the Posttranslational Level | Q38323301 | ||
| Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines | Q38335399 | ||
| Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells | Q38360859 | ||
| Stat3 activation by Src induces specific gene regulation and is required for cell transformation | Q39583802 | ||
| Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor | Q39717742 | ||
| Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy | Q40508006 | ||
| Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. | Q40724591 | ||
| Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis | Q40755904 | ||
| Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells | Q40821355 | ||
| Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling | Q40837817 | ||
| Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway . | Q40905632 | ||
| IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway | Q40911421 | ||
| Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells | Q40972355 | ||
| STATs and MAPKs: obligate or opportunistic partners in signaling | Q41147086 | ||
| Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. | Q41153893 | ||
| Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein | Q41326706 | ||
| Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation | Q41526707 | ||
| Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity | Q42496223 | ||
| Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. | Q42833476 | ||
| VEGF differentially activates STAT3 in microvascular endothelial cells | Q44489900 | ||
| Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. | Q45863133 | ||
| Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders | Q46913469 | ||
| Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation | Q47745076 | ||
| Cooperation between STAT3 and c-jun suppresses Fas transcription. | Q50335898 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 119-125 | |
| P577 | publication date | 2012-07-04 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects | |
| P478 | volume | 5 |
| Q34443746 | Activation of miR-21 by STAT3 induces proliferation and suppresses apoptosis in nasopharyngeal carcinoma by targeting PTEN gene |
| Q37148218 | Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling |
| Q41816821 | Cetuximab induces eme1-mediated DNA repair: a novel mechanism for cetuximab resistance |
| Q38915711 | Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets |
| Q39024619 | Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro |
| Q33718420 | Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells |
| Q37725643 | Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer |
| Q28394712 | RETRACTED ARTICLE: Oncogenic transformation of human lung bronchial epithelial cells induced by arsenic involves ROS-dependent activation of STAT3-miR-21-PDCD4 mechanism |
| Q36061481 | SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells |
| Q60925541 | Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways |
| Q37705457 | Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. |
| Q42413218 | Theaflavins suppress tumor growth and metastasis via the blockage of the STAT3 pathway in hepatocellular carcinoma |
Search more.